Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05923073 · ClinicalTrials.gov registry record · Phase 3
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
A Phase 3 study of Crohn's Disease, sponsored by Janssen Research & Development.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 120
- Enrollment target
- 20
- Study locations
NCT05923073 is a Phase 3 study of Crohn's Disease that is actively recruiting participants, run by Janssen Research & Development. The registered enrollment target is 120 participants, below the 2,414-participant average among 104 other Crohn's Disease trials with a reported enrollment target (95% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT05923073, a Phase 3 study of Crohn's Disease, is actively recruiting participants, sponsored by Janssen Research & Development.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 120 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the clinical and endoscopic efficacy of guselkumab in pediatric participants with Crohn's Disease (CD) at the end of maintenance therapy (Week 52) among participants who were in clinical response to guselkumab at Week 12.
Conditions Studied
Interventions
- DRUG Guselkumab
Study Locations (20)
Other
- Mater Hospital Brisbane - South Brisbane
- The Children's Hospital at Westmead - Westmead
- AKH - Medizinische Universitat Wien - Vienna
- Universitair Ziekenhuis Brussel - Brussels
- Cliniques Universitaires Saint Luc - Brussels
- Universitair Ziekenhuis Gent - Ghent
- UZ Leuven - Leuven
New York
- Weill Cornell Medical College - Judith Jaffe Multiple Sclerosis Center - New York
- Icahn School of Medicine at Mount Sinai - New York
- Columbia University Medical Center - New York
Georgia
- Emory University - Atlanta
- Children's Center for Digestive Health Care - Atlanta
California
- Cedars Sinai Medical Center - Los Angeles
Connecticut
- Connecticut Children's Medical Center - Hartford
Indiana
- Riley Hospital for Children - Indianapolis
Massachusetts
- Boston Childrens Hospital - Boston
Ohio
- The Children's Medical Center of Dayton - Dayton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2024-03-13 |
| Est. Completion | 2028-07-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05923073
The ClinicalTrials.gov registry entry for NCT05923073 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,414-participant average among 104 other Crohn's Disease trials with a reported enrollment target (95% lower). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Crohn's Disease appearing as the primary indexed condition, and to 1 intervention - of which Guselkumab is the first listed.
NCT05923073 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Other, New York, Georgia.
Frequently Asked Questions
What is clinical trial NCT05923073 about?
NCT05923073 is a clinical study titled "A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease". The purpose of this study is to evaluate the clinical and endoscopic efficacy of guselkumab in pediatric participants with Crohn's Disease (CD) at the end of maintenance therapy (Week 52) among participants who were in clinical response to guselkumab at Week 12.
What is the current status of trial NCT05923073?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 120 participants. The study started on 2024-03-13. Estimated completion is 2028-07-12.
What conditions does trial NCT05923073 study?
This clinical trial studies the following conditions: Crohn's Disease.
What interventions are being tested in trial NCT05923073?
The interventions under investigation include: Guselkumab (DRUG).
Who is sponsoring clinical trial NCT05923073?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05923073 being conducted?
This trial has 20 study locations across California, Connecticut, Georgia, Indiana, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Crohn's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease
RECRUITING · Phase 3
-
Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients
RECRUITING · Phase 3
-
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
RECRUITING · Phase 3
-
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
RECRUITING · Phase 3
-
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
RECRUITING · Phase 3
-
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.